Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer



Gastric & Breast Cancer
DOI: 10.2122/gbc.2002.0007

EDITORIAL
February, 2002

Optimizing Lymph Node Dissection for Gastric Cancer

ABSTRACT

Although extended (D2) lymph node dissection is often required for curative surgery, that is the treatment of choice for gastric cancer, its therapeutic value has not yet been established. The effect of lymph node dissection on short-term outcome (morbidity, mortality) and long-term survival is still highly debated. A preliminary report of a recently completed Japanese randomized trial (4th IGCC, 2002), in contrast to the two European randomized trials available (N Engl J Med 1999;340:908-14, Br J Cancer 1999;79:1522-30), provides evidence for the safety of extended lymph node dissection when two conditions are met: experience of surgeon and standardized pancreas-preserving technique. However, whether D2 dissection, as compared with limited (D1) dissection, significantly reduces recurrence-risk and improves survival needs further evidence-based evaluation. This assessment is very complex and represents the current challenge of evaluation because several factors including stage migration confound even randomized comparisons of D1 and D2 resections.

Alternatively, the benefits of D2 dissection can be evaluated on the basis of a recently described concept (Surgery 1998;123:573-8). Key points are the calculations of (1) quantity of lymph nodes dissected by D2 and left behind by D1 dissection (celiac axis/hepatoduodenal ligament). (2) the magnitude of metastatic disease-risk in these level II (N2) nodes that reflects the D1 dissection-attributable risk of residual disease and (3) survival rate of these N2 patients after curative D2 dissection. These calculations (Ann Surg Oncol 2000;7:253-5), which have received little attention by the literature, indicate that 1 additional life would be saved for every 13 patients treated with curative D2 dissection. Furthermore, the benefit of D2 dissection might be greater if micrometastatic disease in level II nodes affect survival but this issue is still controversial.

Taken together all these data a decision about the extent of optimal lymph node dissection in the individual patient with gastric cancer can be made.

Six figures clearly show the benefit of D2 vs. D1 dissection from surgical-oncological point of view. This is the additional fatty-connective tissue, with containing level II nodes, removed from celiac axis (superior border of pancreas) and hepatoduodenal ligament by D2 and left behind by D1 dissection.

Full Text

Comments and questions? Please contact us.

The Gastric Breast Cancer Network Center is owned, published, and copyrighted 2002. All rights reserved.

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 22 May 2003